Navigation Links
deCODE Conducting Strategic Review to Sharpen the Focus of its Long-term Business
Date:10/15/2008

tements contained in this presentation that relate to future plans, events or performance are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results, and the timing of events, to differ materially from those described in the forward-looking statements. These risks and uncertainties include, among others, those relating to our ability to obtain financing and to form collaborative relationships, the effect of a potential delisting of our common stock from The Nasdaq Global Market, uncertainty regarding potential future deterioration in the market for auction rate securities which could negatively affect our cash position and result in additional permanent impairment charges, our ability to develop and market diagnostic products, the level of third party reimbursement for our products, risks related to preclinical and clinical development of pharmaceutical products, including the identification of compounds and the completion of clinical trials, the effect of government regulation and the regulatory approval processes, market acceptance, our ability to obtain and protect intellectual property rights for our products, dependence on collaborative relationships, the effect of competitive products, industry trends and other risks identified in deCODE's filings with the Securities and Exchange Commission, including, without limitation, the risk factors identified in our most recent Annual Report on Form 10-K and any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. deCODE undertakes no obligation to update or alter these forward-looking statements as a result of new information, future events or otherwise.

Contacts:

Edward Farmer Joy Bessenger Gisli Arnason

+354 570 2819 +1 212 481
'/>"/>

SOURCE deCODE genetics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. deCODE Launches deCODE BreastCancer(TM), a Genetic Test to Screen for Risk of the Common Forms of Breast Cancer
2. Open Biosystems Launches Decode RNAi Viral Screening Pools for Low-Cost Genome-Scale RNAi Screens
3. deCODE genetics to Webcast Presentation at Piper Jaffray Annual Healthcare Conference
4. deCODE genetics to Webcast Presentation at Lazard Capital Markets Annual Healthcare Conference
5. Wound Management Technologies, Inc. Announces Strategic Plans for Revenue Growth for Year End and 2009
6. Herley Industries, Inc. Engages Jefferies Quarterdeck to Explore Strategic Alternatives
7. ReachMD, LLC Announces New Strategic Partnership With The American Medical Student Association
8. Marex Group Forms Business Development Department and Promotes Three Strategic Employees
9. Covance and Lilly Enter Into a Strategic R&D Collaboration
10. U.S. Preventive Medicine(R) Forms Strategic Alliance with Physicians Planning Group
11. InfoLogix Launches Strategic Mobility Assessment Service for Hospitals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... CA (PRWEB) September 22, 2014 ... course from Winter & Alvin has just been ... excitement throughout the personal development community. The media ... attention of HonestyFirstReviews.com's Tiffany Hendricks prompting an investigative ... topic of great interest for many entrepreneurs and ...
(Date:9/22/2014)... 22, 2014 QueenBeeTickets.com has the largest ... larger with discount Stevie Wonder tickets. The phenomenal singer/songwriter ... Tour,” and 11 cities have been put on the ... , Click Here to view the selection ... , Stevie Wonder ticket sales are bound to be ...
(Date:9/22/2014)... AttorneyOne.com, a recognized authority on law, update the ... on Twix . , Mars Chocolate North America announced ... Stand Up Pouch with specific code date are recalled due ... is that Twix Unwrapped Bites 7 oz. Stand Up Pouch ... writing them on the ingredient label. , In case ...
(Date:9/22/2014)... 2014 The Center for Health ... ERC as one of the NorthCoast 99 ... places to work for top talent. This award recognizes ... maintain great workplaces that support the attraction, retention and ... staffing and workforce, development and training, compensation and rewards, ...
(Date:9/22/2014)... The Ruby Report was launched by the ... Conference in Louisville, Kentucky. This release followed the May ... reception attended by 60 people from the local area. ... gained while conducting her research, what drove her to ... and what she believes companies can do to be ...
Breaking Medicine News(10 mins):Health News:"The Millionaire's Brain" - A Review Examining Winter & Alvin's Training Course Released 2Health News:Discount Stevie Wonder Tickets: QueenBeeTickets.com Delights Customers with Discounted Concert Tickets for Stevie Wonder’s 11-City Tour Set to Kick off in November 2Health News:Mars Chocolate North America Recalls Twix Bites: AttorneyOne Monitors and Keeps Consumers Informed 2Health News:The Center for Health Affairs Named to 2014 NorthCoast 99 List 2Health News:The Center for Health Affairs Named to 2014 NorthCoast 99 List 3Health News:Ruby Report Book Launch Reveals Critical Insights on Gender Intelligence 2
... 10 Caliper Life Sciences, Inc. (Nasdaq: ... at the Cowen and Company 29th Annual Health ... on Tuesday, March 17 at 10:15 a.m. ET. ... will be providing an update on the company,s ...
... Report Finds Public Health Programs At Risk During Economic ... and the Robert Wood Johnson Foundation (RWJF) today released ... received less funding from the federal government than Northeastern ... for disease prevention programs, which can amount to millions ...
... Designed to Optimize Treatment of Patients with Coronary ... Abbott ( NYSE: ABT ) today announced ... a next-generation balloon dilatation catheter with high-pressure capability ... coronary artery disease (CAD) during angioplasty procedures. VOYAGER ...
... 10 Johnson & Johnson will participate in the ... Monday, March 16th at the Boston Marriott Copley Place ... President, Finance and Chief Financial Officer, will represent the ... Time). The webcast will be available to investors and ...
... 10 The Kavli Foundation has announced the appointment ... - only the second president since the Foundation was ... Foundation,s President in late April of this year.Dr. Conn ... acclaimed scientist whose research is focused on plasma physics ...
... in the March issue of the Journal of ... transplantation should be used with caution in patients older ... with high rates of mortality after one year in ... the gold-standard treatment for a variety of end-stage lung ...
Cached Medicine News:Health News:Midwestern and Southern States Receive Least Federal Funding for Disease Prevention 2Health News:Midwestern and Southern States Receive Least Federal Funding for Disease Prevention 3Health News:Midwestern and Southern States Receive Least Federal Funding for Disease Prevention 4Health News:Abbott Launches VOYAGER(TM) NC Coronary Balloon Catheter 2Health News:Abbott Launches VOYAGER(TM) NC Coronary Balloon Catheter 3Health News:Abbott Launches VOYAGER(TM) NC Coronary Balloon Catheter 4Health News:Abbott Launches VOYAGER(TM) NC Coronary Balloon Catheter 5Health News:Dr. Robert W. Conn Named President of The Kavli Foundation 2Health News:Dr. Robert W. Conn Named President of The Kavli Foundation 3Health News:Dr. Robert W. Conn Named President of The Kavli Foundation 4Health News:Journal of American College of Surgeons finds lung transplantation should be used in older patients 2
(Date:9/19/2014)... 2014 UBM Medica US announces that  ... to help oncologists and other clinicians gain a better ... of targeted therapies and immunotherapies, discusses some of the ... Every September, Blood Cancer Awareness Month ... about blood cancers—helping to increase survival rates and improve ...
(Date:9/19/2014)... 19, 2014  Pressure BioSciences, Inc. (OTCQB: PBIO) ... received and approved all parts required to build ... begun to manufacture the new PCT-based instrument system.  ... ready for shipment by mid-October and that additional ... a rate of about one per week thereafter.  ...
(Date:9/19/2014)... , Sept. 19, 2014  Over 200 runners ... Future to Benefit the Radiation Oncology Institute (ROI), hosted ... at Golden Gate Park in San Francisco.  ... Moore , CEO of Radiation Business Solutions, "but ... have raised over $70,000 for the ROI this year. ...
Breaking Medicine Technology:OncoTherapy Network Highlights National Blood Cancer Awareness Month 2OncoTherapy Network Highlights National Blood Cancer Awareness Month 3OncoTherapy Network Highlights National Blood Cancer Awareness Month 4Pressure BioSciences Announces Completion of the First Phase of Its Commercialization Plan for the Barozyme HT48, the Company's Recently Released High Throughput PCT-based Instrument System 2Pressure BioSciences Announces Completion of the First Phase of Its Commercialization Plan for the Barozyme HT48, the Company's Recently Released High Throughput PCT-based Instrument System 3Fifth Annual 5K Run for the Future to Benefit the Radiation Oncology Institute Breaks Attendance, Donation Records 2Fifth Annual 5K Run for the Future to Benefit the Radiation Oncology Institute Breaks Attendance, Donation Records 3
... CHADDS FORD, Pa., Oct. 22 Endo Pharmaceuticals (Nasdaq: ... and Company 21st Annual Healthcare Conference on Tuesday, November 2, 2010, ... Endo, will review the company,s products and development programs. ... from Endo,s website at www.endo.com under the investors section. ...
... Pharmaxis (ASX: PXS) today announced significant results of pooled ... III trials of Bronchitol (inhaled mannitol) in people with ... presented for the first time at the North American ... addition, more results from the second trial (CF302) have ...
Cached Medicine Technology:Pharmaxis Announces Positive Combined Phase 3 Cystic Fibrosis Trial Results 2Pharmaxis Announces Positive Combined Phase 3 Cystic Fibrosis Trial Results 3Pharmaxis Announces Positive Combined Phase 3 Cystic Fibrosis Trial Results 4Pharmaxis Announces Positive Combined Phase 3 Cystic Fibrosis Trial Results 5
... enzyme immunoassay kit for the quantitative ... in serum. Enzyme immunoassay (EIA) permits ... protein hormones in body fluids and ... and specific assay. This enzyme immunoassay ...
SHIONORIA BNP,is a reagent used in the measurement of blood BNP. The blood BNP test allows accurate estimation of coronary functions....
... immunosorbent assay method for the semi-quantitative ... myeloperoxidase in human serum. The results ... used as an aid in the ... conditions associated with elevated anti-neutrophil cytoplasmic ...
... The determination of Ang II ... monitoring the pharmacological effect and ... of angiotensin converting enzyme inhibitors ... receptor antagonists as well as ...
Medicine Products: